anti-integrin antibodies
ApprovedSmall molecule
anti-integrin antibodies is one of 42 small molecule programs targeting Inflammatory Bowel Disease. It is currently in Approved.
2
Indications
2
Total Trials
2
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
151 competitors in Inflammatory Bowel Disease
#DrugCompanyPhaseTrials
1Remicade
OOrganon and Co
Phase 3
Stelara
Johnson & JohnsonPhase 3
Thalomid
Bristol-Myers SquibbPhase 3
Farxiga
AstraZenecaPhase 3
Humira
CCelltrion
Phase 3
Omvoh
Eli LillyPhase 3
Valcyte
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Jyseleca
GileadPhase 2
Iron Sulphate
PPierre Fabre Pharma GmbH
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anti-integrin antibodies. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- PPeking University First Hospital